Advertisement

Picture Berlin Partner HealthCapital RegMed Forum 2018 October 600x60px
Document › Details

Evonik Industries AG. (1/9/15). "Press Release: New Chief Innovation Officer at Evonik". Essen.

Organisation Organisation Evonik Industries AG
  Group Evonik (Group)
Products Product CHEMICALS
  Product 2 industrial biotechnology
Persons Person Küsthardt, Ulrich (Evonik 201501– Chief Innovation Officer joined Evonik 1997)
  Person 2 Nagler, Peter (Evonik 201201 Chief Innovation Officer)
     


Dr. Ulrich Küsthardt has been the new chief innovation officer at Evonik since the beginning of this year. Küsthardt, who succeeds Dr. Peter Nagler, plans to continue strengthening the company’s innovation capacity, continuing his predecessor’s successful work. “Our strategy must be aimed at stimulating Evonik’s growth with attractive fields of innovation. We want to be one of the world’s most innovative companies,” Küsthardt said. Dr. Nagler will remain involved with the topic of innovation and step up efforts to internationalize innovation at Evonik in the future.

Küsthardt, who holds a doctorate in chemistry, began his career at an international consulting firm. Starting in 1997, he held positions at a predecessor of Evonik, initially in controlling as well as in marketing and sales. He later went on to manage various business units, heading up the Coatings & Additives Business Unit of Evonik Industries from 2008.

Innovations are an essential driver for profitable growth at Evonik. They pave the way for new areas of business and strengthen leading market and technology positions. The innovation pipeline of the specialty chemicals company is well-filled with roughly 500 short-, medium-, and long-term projects. To keep up the flow of ideas and innovations in the future, too, the Group has increased its spending on research and development by an average of nine percent per year since 2009. R&D spending in 2013 totaled €394 million.


Company information

Evonik, the creative industrial group from Germany, is one of the world leaders
in specialty chemicals. Profitable growth and a sustained increase in the value of the company form the heart of Evonik’s corporate strategy. Its activities focus on the key megatrends health, nutrition, resource efficiency and globalization. Evonik benefits specifically from its innovative prowess and integrated technology platforms.

Evonik is active in over 100 countries around the world. In fiscal 2013 more than 33,500 employees generated sales of around €12.7 billion and an operating profit (adjusted EBITDA) of about €2.0 billion.


Disclaimer

In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.



Contacts

Business Contact
Dr. Edda Schulze
Corporate Press
+49 201 177-2555
+49 201 177-3030

Specialized Press Contact
Stefan Cornelissen
Corporate Innovation
+49 201 177-4327
+49 201 177-4322

   
Record changed: 2017-04-02

Advertisement

Picture EBD Group Bio-Europe 2018 Copenhagen Denmark November 600x60px

More documents for Evonik (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture Berlin Partner HealthCapital RegMed Forum 2018 October 600x60px




» top